Why This Seattle Biotech Could be an M&A Target Post author:Sam Post published:January 18, 2018 Post category:BioPharma Immune Design is a clinical-stage immunotherapy company. Source: BioSpace You Might Also Like Former Biotech CEO Accused of Defrauding Investors August 1, 2017 Delcath Systems Announces Adjournment Of Annual Meeting Meeting Scheduled To Reconvene On June 16 June 5, 2017 Watch Out! Novartis AG Hungry for Small Takeover Targets With Early-Stage Drugs January 24, 2017
Delcath Systems Announces Adjournment Of Annual Meeting Meeting Scheduled To Reconvene On June 16 June 5, 2017
